Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review [PDF]
Dermatology and Therapy, 2023 Finasteride and dutasteride are 5-alpha reductase selective inhibitors (5ARIs). They were introduced as therapeutic agents for the treatment of benign prostatic hyperplasia in 1992 and 2002, respectively; finasteride has also been approved for the ...
Mariana Escamilla-Cruz +3 more
doaj +2 more sources
5-alpha reductase inhibitors and MRI prostates: actively reducing prostate sizes and ambiguity [PDF]
BMC Urology, 2023 Background Magnetic resonance imaging (MRI) scans are increasingly first-line investigations for suspected prostate cancer, and essential in the decision for biopsy.
Ziting Wang +5 more
doaj +2 more sources
Do Alpha-Blockers and 5-Alpha Reductase Inhibitors Increase Dementia Risk? A Network Meta-analysis [PDF]
International Neurourology JournalPurpose Alpha-blockers and 5-alpha reductase inhibitors (5ARIs) are well-established treatments for symptoms of benign prostatic hyperplasia (BPH). Despite their therapeutic benefits, concerns have been raised regarding a potential association between ...
Karmenia Jessica Kurnia Niaga +7 more
doaj +2 more sources
Using 5 alpha reductase inhibitors safely: What primary care physicians need to know [PDF]
Journal of Family Medicine and Primary Care5 Alpha Reductase Inhibitor (ARI) is a widely used class of medication; for benign prostatic hypertrophy, androgenetic alopecia and hirsutism. While generally considered safe, ARIs class of medication does have a number of side effects, which can ...
Senthil R. Meenrajan
doaj +2 more sources
Monitoring of prostate-specific antigen in men with benign prostate enlargement receiving 5-alpha reductase inhibitors: a non-interventional, cross-sectional study of real-world practice of urologists in Spain and Brazil [PDF]
BMC UrologyBackground Inconsistent monitoring of prostate-specific antigen in patients receiving 5-alpha reductase inhibitors for lower urinary tract symptoms/benign prostate enlargement may affect prostate cancer outcomes.
Juan Manuel Palacios +7 more
doaj +2 more sources
Drug-Induced Melasma in Patients on 5-Alpha Reductase Inhibitors: A Case Report [PDF]
Case Reports in DermatologyIntroduction: Melasma is a chronic hyperpigmentation disorder with pathogenesis linked to hormonal mediation, ultraviolet and heat exposure, and genetic predisposition.
Hiba Elhaj +2 more
doaj +2 more sources
5 Alpha Reductase Inhibitors (5ARIs) Monotherapy and Combinations: Current Role in Benign Prostatic Hyperplasia (BPH) Management [PDF]
MedicinaBackground and Objectives: Benign prostatic hyperplasia (BPH) is a progressive, androgen-dependent condition driven by dihydrotestosterone (DHT). 5α-reductase inhibitors (5-ARIs), including finasteride and dutasteride, target this pathway and provide ...
Christos Roidos +4 more
doaj +2 more sources
Prognostic influence of 5 alpha reductase inhibitors in patients with localized prostate cancer under active surveillance [PDF]
Urology Research and Practice, 2019 Objective: The incidence of prostate adenocarcinoma (PCa) is increased with the use of prostate-specific antigen (PSA). In the current study, we aimed to investigate the impact of 5- alpha- reductase inhibitors (5-ARI) on pathological progression in ...
Tayyar Alp Özkan +3 more
doaj +2 more sources
Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection [PDF]
BiomoleculesConcerns exist regarding the effects of 5-alpha reductase inhibitors (5-ARIs) on multipa-rametric magnetic resonance imaging (mpMRI) and clinically significant prostate cancer (csPCa) detection.
Juan Morote +10 more
doaj +2 more sources
Management of patients with lower urinary tract symptoms due to benign prostatic enlargement at risk of progression treated with 5-alpha-reductase inhibitors: examining real-world clinical practice in Spain and Brazil [PDF]
BMC UrologyBackground For patients with lower urinary tract symptoms due to benign prostatic enlargement (LUTS/BPE), assessing patient risk of disease progression is important to determine if treatment with 5-alpha-reductase inhibitors (5ARIs) is warranted ...
Juan Manuel Palacios +7 more
doaj +2 more sources